Compare Heron Therapeutics Inc (HRTX) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs ProShares UltraPro S&P500 — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while ProShares UltraPro S&P500 trades at $142.05. The key difference: ProShares UltraPro S&P500 is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | UPRO | |
|---|---|---|
Market Cap | $91.46M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.96 | $150.93 |
52-Week Low | $0.39 | $89.29 |
Enterprise Value | $189.36M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
UPRO trades at $138.50, down 0.4% on the day, with a bearish technical signal driven by moving averages. Key support lies at $135, while resistance is at $141. Financial ratios are unavailable, limiting fundamental clarity. Recent news highlights S&P 500 concentration risks and AI-driven market volatility, influencing this leveraged ETF's performance.
The outlook is cautious due to technical weakness and broader market concerns over valuation and tech stock reliance. Risks include market corrections and ETF-specific volatility. Investors should weigh the lack of fundamental data against the leveraged exposure to S&P 500 trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
